Hiroshi Yukawa

Dr. Hiroshi Yukawa

Department of Applied Chemistry, School of Engineering, Nagoya University, Furocho, Chikusa Ward, Nagoya, Aichi 464-8601, Japan
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2017 in Analytical Chemistry
Verified
Journal Article
Closed access
Hiroshi YukawaHiroshi Yukawa
Hiroshi Yukawa
YBYoshinobu Baba
Yoshinobu Baba

3 April 2020 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
Hiroshi YukawaHiroshi Yukawa
Hiroshi Yukawa
Masazumi FujiwaraMasazumi Fujiwara
Masazumi Fujiwara
KKKaori Kobayashi
Kaori Kobayashi
YKYuka Kumon
Yuka Kumon
KMKazu Miyaji
Kazu Miyaji
YBYoshinobu Baba
Yoshinobu Baba
Intracellular thermometry techniques play an important role in elucidating the relationship between the intracellular temperature and stem cell functions. However, there have been few reports on thermometry techniques that can detect the intracellular temperature of cells during several days of incubation. In this study, we developed a novel quantum thermometric sensing and analysis system (QTAS) using fluorescent nanodiamonds (FNDs). FNDs could label adipose tissue-derived stem cells (ASCs) at high efficiency with 24 h of incubation, and no cytotoxicity was observed in ASCs labeled with less than 500 μg mL−1 of FNDs. The peak of FNDs was confirmed at approximately 2.87 GHz with the characteristic fluorescence spectra of NV centers that could be optically detected (optically detected magnetic resonance [ODMR]). The ODMR peak clearly shifted to the high-frequency side as the temperature decreased and gave a mean temperature dependence of −(77.6 ± 11.0) kHz °C−1, thus the intracellular temperature of living ASCs during several days of culturing could be precisely measured using the QTAS. Moreover, the intracellular temperature was found to influence the production of growth factors and the degree of differentiation into adipocytes and osteocytes. These data suggest that the QTAS can be used to investigate the relationship between intracellular temperature and cellular functions.

20 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
YNYuko Nishinaga
Yuko Nishinaga
Kazuhide SatoKazuhide Sato
Kazuhide Sato
HYHirotoshi Yasui
Hirotoshi Yasui
STShunichi Taki
Shunichi Taki
KTKazuomi Takahashi
Kazuomi Takahashi
YHYoshinori Hasegawa
Yoshinori Hasegawa
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable. Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer therapy that combines the specificity of antibodies for targeting tumors with toxicity induced by the photoabsorber after exposure to NIR-light. In this study, we developed a new phototherapy targeting podoplanin (PDPN) for MPM with the use of both NIR-PIT and an anti-PDPN antibody, NZ-1. An antibody–photosensitizer conjugate consisting of NZ-1 and phthalocyanine dye was synthesized. In vitro NIR-PIT-induced cytotoxicity was measured with both dead cell staining and luciferase activity on various MPM cell lines. In vivo NIR-PIT was examined in both the flank tumor and orthotopic mouse model with in vivo real-time imaging. In vitro NIR-PIT-induced cytotoxicity was NIR-light dose dependent. In vivo NIR-PIT led to significant reduction in both tumor volume and luciferase activity in a flank model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). The PDPN-targeted NIR-PIT resulted in a significant antitumor effect in an MPM orthotopic mouse model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). This study suggests that PDPN-targeted NIR-PIT could be a new promising treatment for MPM.

30 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Hiroshi YukawaHiroshi Yukawa
Hiroshi Yukawa
KSKaoru Suzuki
Kaoru Suzuki
KAKeita Aoki
Keita Aoki
TATomoko Arimoto
Tomoko Arimoto
TYTakao Yasui
Takao Yasui
YBYoshinobu Baba
Yoshinobu Baba
Hepatocellular carcinoma (HCC) is a typical hyper-vascular tumor, so the understanding the mechanisms of angiogenesis in HCC is very important for its treatment. However, the influence of the exosomes secreted from HCC cells (HCC-exosomes) on angiogenesis remains poorly understood. We herein examined the effects of the exosomes secreted from HepG2 cells (HepG2-exosomes) on the lumen formation of human umbilical vein endothelial cells (HUVECs) by the imaging of angiogenesis. The degree of lumen formation of HUVECs was dependent on the number of HepG2-exosomes. The HepG2-exosomes expressed NKG2D, an activating receptor for immune cells, and HSP70, a stress-induced heat shock protein associated with angiogenesis through the vascular endothelial growth factor (VEGF) receptor. In addition, the HepG2-exosomes contained several microRNAs (miRNAs) reported to exist in the serum of HCC patients. These results suggest that the HCC-exosomes play an important role in angiogenesis. Further studies on the function of HCC-exosomes may provide a new target for HCC treatment.

6 May 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
Hiroshi YukawaHiroshi Yukawa
Hiroshi Yukawa
KSKazuhide Sato
Kazuhide Sato
YBYoshinobu Baba
Yoshinobu Baba
Quantum dots (QDs) have attracted attention for their application and commercialization in all industrial fields, including communications, displays, and solar cells, due to their excellent optical properties based on the quantum size effect. In recent years, the development of QDs that do not contain cadmium which is toxic to cells and living organisms, has progressed, and they have attracted considerable attention in the bio-imaging field for targeting molecules and cells. Furthermore, recently, the need for diagnostics and treatment at the single molecule and single cell level in the medical field has been increasing, and the application of QDs in the medical field is also accelerating. Therefore, this paper outlines the frontiers of diagnostic and therapeutic applications (theranostics) of QDs, especially in advanced medical fields such as regenerative medicine, oncology, and infectious diseases.

25 July 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
MLMinchuan Luo
Minchuan Luo
Hiroshi YukawaHiroshi Yukawa
Hiroshi Yukawa
Kazuhide SatoKazuhide Sato
Kazuhide Sato
MTMakoto Tozawa
Makoto Tozawa
MTMasato Tokunaga
Masato Tokunaga
YBYoshinobu Baba
Yoshinobu Baba
Chemodynamic therapy (CDT), which consumes endogenous hydrogen peroxide (H2O2) to generate reactive oxygen species (ROS) and causes oxidative damage to tumor cells, shows tremendous promise for advanced cancer treatment. However, the rate of ROS generation based on the Fenton reaction is prone to being restricted by inadequate H2O2 and unattainable acidity in the hypoxic tumor microenvironment. We herein report a multifunctional nanoprobe (BCGCR) integrating bimodal imaging and photothermal-enhanced CDT of the targeted tumor, which is produced by covalent conjugation of bovine serum albumin-stabilized CuS/Gd2O3 nanoparticles (NPs) with the Cy5.5 fluorophore and the tumor-targeting ligand RGD. BCGCR exhibits intense near-infrared (NIR) fluorescence and acceptable r1 relaxivity (∼15.3 mM-1 s-1) for both sensitive fluorescence imaging and high-spatial-resolution magnetic resonance imaging of tumors in living mice. Moreover, owing to the strong NIR absorbance from the internal CuS NPs, BCGCR can generate localized heat and displays a high photothermal conversion efficiency (30.3%) under 980 nm laser irradiation, which enables photothermal therapy and further intensifies ROS generation arising from the Cu-induced Fenton-like reaction for enhanced CDT. This synergetic effect shows such an excellent therapeutic efficacy that it can ablate xenografted tumors in vivo. We believe that this strategy will be beneficial to exploring other advanced nanomaterials for the clinical application of multimodal imaging-guided synergetic cancer therapies.